Paper Details

  1. Home
  2. Paper Details

Topical levocabastine, a selective H1 antagonist, in seasonal allergic rhinoconjunctivitis.

Author: BendeM, PipkornU

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Levocabastine, a selective H1 antagonist, was found to be effective in treating allergic rhinoconjunctivitis, with fewer side effects compared to other treatments.
Paper Details　
Original Abstract of the Article :
Sixty-six patients with seasonal allergic rhinitis due to birch pollens, participated in an efficacy evaluation of topically applied, nasal and ocular, levocabastine, a highly selective H1 antagonist. A single blind comparison was performed between nasal levocabastine and flunisolide, a topical gluc...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1398-9995.1987.tb00374.x

データ提供：米国国立医学図書館（NLM）

Taming the Itch: Topical Levocabastine for Seasonal Allergic Rhinoconjunctivitis

Seasonal allergic rhinoconjunctivitis (SAR), often referred to as hay fever, is a common ailment that brings about a cascade of uncomfortable symptoms, including sneezing, runny nose, and itchy eyes. These symptoms can be like sandstorms, making it difficult to enjoy the beauty of the world around us. This study focuses on the effectiveness of topical levocabastine, a selective H1 antagonist, for treating SAR, offering a potential solution to alleviate these bothersome symptoms.

A Cool Breeze in the Desert of Allergies: Levocabastine's Efficacy

The researchers conducted a single-blind comparison study involving 66 patients with SAR due to birch pollens. They compared the efficacy of nasal levocabastine to flunisolide, a topical glucocorticoid, and ocular levocabastine to naphazoline/antazoline eye drops. The results showed that topical levocabastine provided significant relief from both nasal and ocular symptoms, offering a welcome respite from the relentless itching and discomfort. While flunisolide outperformed levocabastine in reducing sneezing, levocabastine emerged as a preferred choice due to its fewer daily administrations and lower incidence of side effects.

A Gentle Touch: Levocabastine's Favorable Side Effect Profile

The researchers found that levocabastine was well-tolerated by the patients, with significantly fewer reports of local irritation compared to the other treatments. This is like finding a gentle breeze amidst the sandstorms of allergy symptoms, offering relief without adding to the discomfort. This favorable side effect profile makes levocabastine a valuable option for patients seeking effective and well-tolerated treatment for SAR.

Dr. Camel's Conclusion

This study demonstrates the potential of topical levocabastine as an effective and well-tolerated treatment for seasonal allergic rhinoconjunctivitis. The researchers have shown that levocabastine offers relief from both nasal and ocular symptoms, making it a valuable tool for patients seeking a comfortable and convenient treatment option. This discovery is like a cool oasis in the desert of allergy discomfort, providing a much-needed respite for those suffering from SAR.

Date :
  1. Date Completed 1987-12-28
  2. Date Revised 2019-08-20
Further Info :

Pubmed ID

2891316

DOI: Digital Object Identifier

10.1111/j.1398-9995.1987.tb00374.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.